Skip to main content
NCBI home page
American Journal of Public Health logoLink to American Journal of Public Health
. 1998 Apr;88(4):551–557. doi: 10.2105/ajph.88.4.551

Trade-offs in prenatal detection of Down syndrome.

M Serra-Prat 1, P Gallo 1, A J Jovell 1, M Aymerich 1, M D Estrada 1
PMCID: PMC1508419  PMID: 9550991

Abstract

OBJECTIVES: This paper presents the results of different screening policies for prenatal detection of Down syndrome that would allow decision makers to make informed choices. METHODS: A decision analysis model was built to compare 8 screening policies with regard to a selected set of outcome measures. Probabilities used in the analysis were obtained from official administrative data reports in Spain and Catalonia and from data published in the medical literature. Sensitivity analyses were carried out to test the robustness of screening policies' results to changes in uptake rates, diagnostic accuracy, and resources consumed. RESULTS: Selected screening policies posed major trades-offs regarding detection rates, false-positive results, fetal loss, and costs of the programs. All outcome measures considered were found quite robust to changes in uptake rates. Sensitivity and specificity rates of screening tests were shown to be the most influential factors in the outcome measures considered. CONCLUSIONS: The disclosed trade-offs emphasize the need to comprehensively inform decision makers about both positive and negative consequences of adopting one screening policy or another.

Full text

PDF
551

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benacerraf B. R., Gelman R., Frigoletto F. D., Jr Sonographic identification of second-trimester fetuses with Down's syndrome. N Engl J Med. 1987 Nov 26;317(22):1371–1376. doi: 10.1056/NEJM198711263172203. [DOI] [PubMed] [Google Scholar]
  2. Burton B. K., Prins G. S., Verp M. S. A prospective trial of prenatal screening for Down syndrome by means of maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol. Am J Obstet Gynecol. 1993 Sep;169(3):526–530. doi: 10.1016/0002-9378(93)90613-n. [DOI] [PubMed] [Google Scholar]
  3. Cheng E. Y., Luthy D. A., Zebelman A. M., Williams M. A., Lieppman R. E., Hickok D. E. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Obstet Gynecol. 1993 Jan;81(1):72–77. [PubMed] [Google Scholar]
  4. Crane J. P., Gray D. L. Sonographically measured nuchal skinfold thickness as a screening tool for Down syndrome: results of a prospective clinical trial. Obstet Gynecol. 1991 Apr;77(4):533–536. [PubMed] [Google Scholar]
  5. Cuckle H. S., Wald N. J., Thompson S. G. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol. 1987 May;94(5):387–402. doi: 10.1111/j.1471-0528.1987.tb03115.x. [DOI] [PubMed] [Google Scholar]
  6. Donnenfeld A. E., Carlson D. E., Palomaki G. E., Librizzi R. J., Weiner S., Platt L. D. Prospective multicenter study of second-trimester nuchal skinfold thickness in unaffected and Down syndrome pregnancies. Obstet Gynecol. 1994 Nov;84(5):844–847. [PubMed] [Google Scholar]
  7. Fletcher J., Hicks N. R., Kay J. D., Boyd P. A. Using decision analysis to compare policies for antenatal screening for Down's syndrome. BMJ. 1995 Aug 5;311(7001):351–356. doi: 10.1136/bmj.311.7001.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ginsberg N., Cadkin A., Pergament E., Verlinsky Y. Ultrasonographic detection of the second-trimester fetus with trisomy 18 and trisomy 21. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1186–1190. doi: 10.1016/0002-9378(90)90686-2. [DOI] [PubMed] [Google Scholar]
  9. Goodburn S. F., Yates J. R., Raggatt P. R., Carr C., Ferguson-Smith M. E., Kershaw A. J., Milton P. J., Ferguson-Smith M. A. Second-trimester maternal serum screening using alpha-fetoprotein, human chorionic gonadotrophin, and unconjugated oestriol: experience of a regional programme. Prenat Diagn. 1994 May;14(5):391–402. doi: 10.1002/pd.1970140509. [DOI] [PubMed] [Google Scholar]
  10. Grandjean H., Sarramon M. F. Sonographic measurement of nuchal skinfold thickness for detection of Down syndrome in the second-trimester fetus: a multicenter prospective study. The AFDPHE Study Group. Association Française pour le Dépistage et la Prévention des Handicaps de l'Enfant. Obstet Gynecol. 1995 Jan;85(1):103–106. doi: 10.1016/0029-7844(94)00327-a. [DOI] [PubMed] [Google Scholar]
  11. Gray D. L., Crane J. P. Optimal nuchal skin-fold thresholds based on gestational age for prenatal detection of Down syndrome. Am J Obstet Gynecol. 1994 Nov;171(5):1282–1286. doi: 10.1016/0002-9378(94)90148-1. [DOI] [PubMed] [Google Scholar]
  12. Haddow J. E., Palomaki G. E., Knight G. J., Cunningham G. C., Lustig L. S., Boyd P. A. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening. N Engl J Med. 1994 Apr 21;330(16):1114–1118. doi: 10.1056/NEJM199404213301603. [DOI] [PubMed] [Google Scholar]
  13. Haddow J. E., Palomaki G. E., Knight G. J., Williams J., Pulkkinen A., Canick J. A., Saller D. N., Jr, Bowers G. B. Prenatal screening for Down's syndrome with use of maternal serum markers. N Engl J Med. 1992 Aug 27;327(9):588–593. doi: 10.1056/NEJM199208273270902. [DOI] [PubMed] [Google Scholar]
  14. Halliday J., Lumley J., Watson L. Comparison of women who do and do not have amniocentesis or chorionic villus sampling. Lancet. 1995 Mar 18;345(8951):704–709. doi: 10.1016/s0140-6736(95)90872-2. [DOI] [PubMed] [Google Scholar]
  15. Lockwood C., Benacerraf B., Krinsky A., Blakemore K., Belanger K., Mahoney M., Hobbins J. A sonographic screening method for Down syndrome. Am J Obstet Gynecol. 1987 Oct;157(4 Pt 1):803–808. doi: 10.1016/s0002-9378(87)80059-5. [DOI] [PubMed] [Google Scholar]
  16. Lynch L., Berkowitz G. S., Chitkara U., Wilkins I. A., Mehalek K. E., Berkowitz R. L. Ultrasound detection of Down syndrome: is it really possible? Obstet Gynecol. 1989 Feb;73(2):267–270. [PubMed] [Google Scholar]
  17. MacDonald M. L., Wagner R. M., Slotnick R. N. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age. Obstet Gynecol. 1991 Jan;77(1):63–68. [PubMed] [Google Scholar]
  18. Mancini G., Perona M., Dall'Amico D., Bollati C., Albano F., Mazzone R., Rosso M., Grosso E., Migone N., Fiocchi F. Maternal serum markers. Estimation of the risk of Down's syndrome: a prospective study. Int J Clin Lab Res. 1994;24(1):49–53. doi: 10.1007/BF02592410. [DOI] [PubMed] [Google Scholar]
  19. Murray D., Tennison B. Decision analysis and screening for Down's syndrome. Estimate of uptake of amniocentesis is overoptimistic. BMJ. 1995 Nov 18;311(7016):1371–1373. doi: 10.1136/bmj.311.7016.1371c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Perrella R., Duerinckx A. J., Grant E. G., Tessler F., Tabsh K., Crandall B. F. Second-trimester sonographic diagnosis of Down syndrome: role of femur-length shortening and nuchal-fold thickening. AJR Am J Roentgenol. 1988 Nov;151(5):981–985. doi: 10.2214/ajr.151.5.981. [DOI] [PubMed] [Google Scholar]
  22. Phillips O. P., Elias S., Shulman L. P., Andersen R. N., Morgan C. D., Simpson J. L. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Obstet Gynecol. 1992 Sep;80(3 Pt 1):353–358. [PubMed] [Google Scholar]
  23. Shackley P., McGuire A., Boyd P. A., Dennis J., Fitchett M., Kay J., Roche M., Wood P. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome. J Public Health Med. 1993 Jun;15(2):175–184. [PubMed] [Google Scholar]
  24. Sonnenberg F. A., Hagerty C. G., Kulikowski C. A. An architecture for knowledge-based construction of decision models. Med Decis Making. 1994 Jan-Mar;14(1):27–39. doi: 10.1177/0272989X9401400104. [DOI] [PubMed] [Google Scholar]
  25. Spencer K., Carpenter P. Risk of Down's syndrome and amniocentesis rate. BMJ. 1992 Mar 7;304(6827):640–641. doi: 10.1136/bmj.304.6827.640-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Spencer K., Coombes E. J., Mallard A. S., Ward A. M. Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem. 1992 Sep;29(Pt 5):506–518. doi: 10.1177/000456329202900504. [DOI] [PubMed] [Google Scholar]
  27. Tabor A., Philip J., Madsen M., Bang J., Obel E. B., Nørgaard-Pedersen B. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet. 1986 Jun 7;1(8493):1287–1293. doi: 10.1016/s0140-6736(86)91218-3. [DOI] [PubMed] [Google Scholar]
  28. Vintzileos A. M., Egan J. F. Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasonography. Am J Obstet Gynecol. 1995 Mar;172(3):837–844. doi: 10.1016/0002-9378(95)90008-x. [DOI] [PubMed] [Google Scholar]
  29. Wald N. J., Cuckle H. S., Densem J. W., Nanchahal K., Royston P., Chard T., Haddow J. E., Knight G. J., Palomaki G. E., Canick J. A. Maternal serum screening for Down's syndrome in early pregnancy. BMJ. 1988 Oct 8;297(6653):883–887. doi: 10.1136/bmj.297.6653.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wald N. J., Kennard A., Densem J. W., Cuckle H. S., Chard T., Butler L. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ. 1992 Aug 15;305(6850):391–394. doi: 10.1136/bmj.305.6850.391. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Public Health are provided here courtesy of American Public Health Association

RESOURCES